🕒 Last update: loading…16/11/2026

Stock Cencora, Inc. COR

Cencora, Inc. — Investlytic score 2/5 on the five criteria.

-
-
40/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 2/5 criteria met. Data as of 01/11/2026.

  • ✅ Price trend passed
  • ⚠️ Mixed growth
  • ❌ Debt failed
  • ✅ P/E passed
  • ❌ Correction failed

Price trend

Overall trend (8 years): the price has been multiplied by at least 1.5.

Price change 2018 → 2019: 14.27%

Price change 2019 → 2020: 14.98%

Price change 2020 → 2021: 35.93%

Price change 2021 → 2022: 24.70%

Price change 2022 → 2023: 23.94%

Price change 2023 → 2024: 9.40%

Price change 2024 → 2025: 50.32%

Price change 2025 → 2026: -1.63%

Price change 2026 (year to date): -1.96%

Financial growth

Revenue CAGR (8 years): 9.71%

Earnings CAGR (8 years): -0.92%

Growth status: positive trend (>1%/yr) in revenue OR earnings, but not both.

Debt

Debt-to-equity ratio: 7.13

Debt/equity > 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: 19.36

P/E < 25.0 (maximum threshold).

Correction (6 months)

Current correction: 3.21% from the high over 6 months.

Insufficient correction (< 10.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Cencora, Inc.19.47.13+9.6 %🔒
Boston Scientific Corporation13.80.51+6.5 %–
Becton, Dickinson and Company16.30.76+6.5 %–
Lonza Group AG41.60.50+6.1 %–
Merck KGaA17.70.42+5.6 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by Cencora, Inc. over the latest fiscal years.

Revenue
337 bn USD
fiscal year 2026
Net income
3.5 bn USD
fiscal year 2026
Net margin
1.0 %
fiscal year 2026
Average annual growth
+9.5 %
Revenue growth over 5 years
Average annual growth
+8.7 %
Revenue growth over 10 years
Market cap
68.5 bn USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
2021214 bn1.5 bn0.7 %n/a
2022239 bn1.7 bn0.7 %+11.5 %
2023262 bn1.7 bn0.7 %+9.9 %
2024294 bn1.5 bn0.5 %+12.1 %
2025321 bn1.6 bn0.5 %+9.3 %
2026337 bn3.5 bn1.0 %+5.0 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by Cencora, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
solid accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
4.49
safe zone (above 2.99)
Piotroski Score
7 / 9
7 to 9: solid accounts
DCF Value
972.08 USD
DCF above share price · share price 349.04 USD, gap +178.5 %
Net Debt / EBITDA
1.04 x
moderate debt
Fiscal year20222023202420252026
Cash and investments3.5 bn2.7 bn3.2 bn4.4 bn4.9 bn
Total Debt7.6 bn6.8 bn6.7 bn9.3 bn11.3 bn
Net Debt4.1 bn4.1 bn3.4 bn4.9 bn6.4 bn
Equity-212 m522 m646 m1.5 bn3.7 bn
Total assets56.6 bn62.6 bn67.1 bn76.6 bn87.1 bn
Operating cash flow2.7 bn3.9 bn3.5 bn3.9 bn4.8 bn
Investments (capex)496 m458 m487 m668 m910 m
Free cash-flow2.2 bn3.5 bn3.0 bn3.2 bn3.9 bn
Share buybacks484 m1.2 bn1.5 bn435 m1.0 bn
Dividends paid392 m399 m416 m437 m477 m

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)19.42 x
Price / book value18.11 x
Return on Equity (ROE)115.8 %
Return on Invested Capital (ROIC)13.5 %
Net margin1.0 %
Debt / equity3.06 x
Current ratio0.94 x
Interest coverage8.36 x
Free cash-flow yield5.8 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 16/11/2026.

+

Valuation and competitors

Cencora, Inc. compared with its sector on the same exchange and with its main competitors.

Company P/E
20.9
24.5 % below the sector
Sector median P/E
27.7
healthcare, NYSE
Sector over 10 years
22.3
10-year median, range 18.4 to 44.9

Direct competitors

CompanyMarket cap (USD)P/ENet margin
Cencora, Inc.63.7 bn19.40.5 %
McKesson Corporation MCK124 bn26.00.9 %
Cardinal Health, Inc. CAH62.9 bn26.10.7 %
Henry Schein, Inc. HSIC9.6 bn16.23.0 %
Sinopharm Group Co. Ltd. SHTDY6.8 bn6.81.2 %
111, Inc. YI25.5 mn/a-0.1 %
Sigma Healthcare Limited SIG.AX22.3 bn46.310.8 %
Sector median (NYSE)27.7

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering Cencora, Inc. publish: ratings, price targets and earnings forecasts.

Majority rating
buy
46 analysts
Average price target
359.50 USD
from 330.00 USD to 400.00 USD, 23 targets over 12 months
Gap with the share price
+7.8 %
price 333.56 USD on 06/11/2026

Breakdown of ratings

strong buy 0buy 33hold 12sell 1strong sell 0

Analysts' average target 359.50 USD, DCF value 972.08 USD, share price 333.56 USD.

Average target over the last 3 months: 366.00 USD (5 targets).

Analyst forecasts

Fiscal yearRevenueNet incomeExpected EPS (range)P/E on this EPSAnalysts
2026337 bn3.5 bn17.89 (17.87 / 17.92)18.67
2027352 bn3.8 bn19.73 (19.40 / 20.04)16.96
2028367 bn4.1 bn21.75 (20.17 / 24.05)15.33

Amounts in USD, the reporting currency.

Track record against expectations: reported EPS above consensus 11 times over the last 12 releases.

Rating changes (12 months)

DateFirmBeforeAfter
10/11/2026JP MorganOverweightOverweight
05/11/2026Evercore ISI GroupOutperformOutperform
05/11/2026Leerink PartnersOutperformOutperform
30/10/2026Morgan StanleyOverweightOverweight
22/10/2026BairdOutperformOutperform

Source: ratings and forecasts published by analysts, collected on 14/11/2026. An analyst rating or target is not a guarantee.

+

Dividends and earnings

Cencora, Inc.: dividend history, last distributions, stock splits and earnings releases.

Frequency
quarterly
Last dividend
0.660 USD
ex-dividend on 13/11/2026
Last 12 months
2.46 USD
number of payments: 4
Yield
0.7 %
on the last known price
Years of increases
22
consecutive
Years of payments
25
uninterrupted
01.082.163.244.322007 : 0.811 USD2008 : 0.163 USD20082009 : 0.240 USD2010 : 0.340 USD20102011 : 0.460 USD2012 : 0.600 USD20122013 : 0.865 USD2014 : 0.995 USD20142015 : 1.63 USD2016 : 1.39 USD20162017 : 2.38 USD2018 : 2.57 USD20182019 : 2.82 USD2020 : 1.70 USD20202021 : 4.32 USD2022 : 1.86 USD20222023 : 1.97 USD2024 : 2.08 USD20242025 : 2.25 USD2026 : 2.46 USD2026

Annual dividend per share (USD), adjusted for splits. Light bar: current year, incomplete. Red bar: lower than the previous year.

Latest ex-dividend dates

Ex-dividendAmountPayment
13/11/20260.660 USD30/11/2026
14/08/20260.600 USD31/08/2026
15/05/20260.600 USD01/06/2026
13/02/20260.600 USD02/03/2026
14/11/20250.600 USD01/12/2025
15/08/20250.550 USD03/09/2025
16/05/20250.550 USD02/06/2025
14/02/20250.550 USD03/03/2025

Earnings releases

DatePublished EPSExpected EPSSurprise
04/11/20264.664.58+1.7 %
05/08/20264.484.35+3.0 %
06/05/20264.754.82-1.5 %
04/02/20264.084.05+0.7 %
05/11/20253.843.79+1.3 %
06/08/20254.003.85+3.9 %

Stock splits

DateOperation
16/06/2009split: 2 shares for 1
29/12/2005split: 2 shares for 1
25/03/1999split: 2 shares for 1

Factual data: ex-dividend history and earnings calendar, as of 15/11/2026. A past dividend does not guarantee the next one.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Cencora, Inc.

Free float
94.5 %
share of freely traded shares
Institutions
94.7 %
1,395 declared holders, 2026Q2
Large funds tracked
28
hold the stock as of 2026Q2
Executives (insiders)
0 / 5
0 purchases, 5 sales in 130 days
US elected officials
8
5 purchases, 3 sales in 12 months

Indices: S&P 500 (since 30/08/2001).

Large funds tracked

FundSharesValue (USD)Weight in the fundChangeQuarter
Vanguard Group23.6 m8.0 bn0.1 %+0.9 %2025Q4
State Street18.5 m5.2 bn0.1 %+101.8 %2026Q2
BlackRock18.2 m5.2 bn0.1 %-8.7 %2026Q2
T. Rowe Price7.1 m2.0 bn0.2 %-2.6 %2026Q2
JPMorgan Chase5.9 m1.7 bn0.1 %+21.7 %2026Q2
Geode Capital Management5.5 m1.5 bn0.1 %-2.0 %2026Q2
Wellington Management4.6 m1.3 bn0.2 %+0.2 %2026Q2
Fidelity4.1 m1.2 bn0.1 %-38.3 %2026Q2

Latest insider transactions

DatePersonSideAmount
02/11/2026Krikorian Lazarussale326,327 USD
01/10/2026Krikorian Lazarussale298,935 USD
16/09/2026Greenberg Lon Rsale411,264 USD
01/09/2026Krikorian Lazarussale321,080 USD
24/08/2026Campbell Elizabeth Ssale3.7 m USD

Elected officials' disclosures

DateOfficialSideAmount
07/10/2026Ro Khannasale$1,001 - $15,000
04/09/2026Ro Khannapurchase$1,001 - $15,000
27/03/2026Alan Armstrongpurchase$1,001 - $15,000
06/05/2026Jared Moskowitzsale$1,001 - $15,000
06/05/2026Jared Moskowitzsale$1,001 - $15,000

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 16/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
NYSE
IPO: 04/04/1995
ISIN code
US03073E1055
Workforce
42,000
full-time employees
Chief executive
Robert P. Mauch PharmD
Next earnings
03/02/2027

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Cencora, Inc.

What is the Cencora, Inc. share price?

Latest recorded price: 359.03 USD on 13/11/2026, for a market cap of 68.5 bn USD.

What is the revenue of Cencora, Inc.?

337 bn USD for fiscal year 2026, with net income of 3.5 bn USD (net margin 1.0 %).

Does Cencora, Inc. pay a dividend?

Yes. Latest dividend: 0.660 USD per share, ex-dividend on 13/11/2026. Over 12 months: 2.46 USD. Yield on the latest known price: 0.7 %.

When does Cencora, Inc. report its next earnings?

The next release is expected on 03/02/2027. EPS expected by analysts: 4.53.

What do analysts say about Cencora, Inc.?

Out of 46 analysts: 33 buy or strong buy, 12 hold, 1 sell or strong sell. Average price target: 359.50 USD, i.e. +7.8 % from the share price.

What is the P/E ratio of Cencora, Inc.?

Trailing 12-month P/E of 20.9, against 27.7 for the sector median on the same exchange (10-year median: 22.3).

Is Cencora, Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US03073E1055).

How many employees does Cencora, Inc. have?

42,000 full-time employees according to the latest published profile.

Who runs Cencora, Inc.?

Robert P. Mauch PharmD is the company's chief executive.

Which large funds own Cencora, Inc.?

As of 2026Q2, among the large funds tracked: Vanguard Group, State Street, BlackRock, T. Rowe Price, JPMorgan Chase.

07

Similar stocks